CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and ...

The U.S. government on Friday proposed 2026 reimbursement rates for Medicare Advantage plans run by private insurers that ...

Zydus Lifesciences reacted sharply to the development in Tuesday's trade with the counter rising 5.23 percent to an intraday high of Rs 1,011.75 per share on the NSE.

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future ...

A state law that went into effect this week aims to regulate the role of third-party pharmacy benefit managers, who many say ...

CVS faces strong competition from Amazon, Walmart, and Costco, impacting market share. Read why I maintain a Hold rating for ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

CVS Health Corp. closed $34.74 short of its 52-week high ($80.75), which the company reached on March 28th.